Take the tablet orally with water immediately before bedtime. Do not chew or crush the tablet. Ensure you have at least 7-8 hours available for sleep after taking the dose.

Zopiclone binds to the GABA-A receptor complex at a site distinct from benzodiazepines but functionally coupled to it. This binding enhances the inhibitory effects of gamma-aminobutyric acid (GABA), leading to central nervous system depression, which manifests as sedative, hypnotic, anxiolytic, anticonvulsant, and muscle relaxant properties.

• •Hypersensitivity to Zopiclone or any component of the formulation
• •Severe respiratory insufficiency
• •Severe hepatic insufficiency
• •Sleep apnea syndrome
• •Myasthenia gravis

Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.

Symptoms of overdose typically include varying degrees of central nervous system depression, ranging from drowsiness to coma, depending on the amount ingested. In mild cases, symptoms include somnolence, confusion, and lethargy. In more severe cases, ataxia, hypotonia, hypotension, methaemoglobinemia, respiratory depression, and coma may occur. Management is primarily supportive, including gastric lavage (if early), activated charcoal, and monitoring vital signs. Flumazenil may be considered as an antidote, but caution is advised in patients on chronic benzodiazepine/Z-drug therapy due to risk of withdrawal seizures.

Pregnancy Category C. Zopiclone should not be used during pregnancy unless the potential benefit outweighs the potential risk to the fetus. If used in late pregnancy, neonatal withdrawal symptoms or 'floppy infant syndrome' may occur. Zopiclone is excreted in breast milk; therefore, it is not recommended for use during lactation.